Fierce Biotech July 29, 2024
With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally.
Venture dollars rose in the second quarter compared to the one prior, according to a new second-quarter licensing and venture report from the bank. Biopharmas raised $7.6 billion in private financings across 107 investments, with the dollar value for both the second and first quarters beating the previous ones. The first quarter also saw 107 total rounds.
“Venture investments returned with high-dollar rounds in Q2 to pour funds into biopharma and platform research, regardless of the company’s clinical status. M&A activity maintained its healthy pace as the IPO market continued to open incrementally wider,” the report...
Today's Sponsors
Today's Sponsor